IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) announced an Investor R&D Day in London on Monday, November 16, 2026, at 5:00 PM GMT, focused on MTAP/CDKN2A and KRAS development strategies in pancreatic cancer, including new preclinical data and combination approaches. The event will feature Dr. Frank McCormick of UCSF and requires advance registration for in-person and virtual attendance. IDEAYA will also participate in several major September 2026 healthcare and biopharma investor conferences in Boston and New York, with multiple fireside chats involving senior management and webcast access via the company’s investor website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 31 | FDA meeting update | Positive | -0.1% | FDA meeting informed planned Phase 3 registrational trial design for IDE849 |
| Aug 28 | Inducement grants | Neutral | -4.0% | Options granted to two newly hired employees under the inducement incentive plan |
| Aug 19 | Clinical collaboration | Positive | +2.5% | Genentech collaboration evaluated IDE892 with GDC-7035 in pancreatic cancer |
| Aug 04 | Second-quarter earnings | Positive | +2.0% | OptimUM-02 met its primary endpoint and NDA filing remained underway |
| Jul 31 | Inducement grants | Neutral | -2.5% | Options granted to fourteen newly hired employees under the inducement incentive plan |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive partnership and earnings announcements aligned with gains, while recent FDA and inducement-grant news diverged from or preceded declines.
Key Terms
mtap/cdkn2a medical
kras medical
tumor heterogeneity medical
adaptive plasticity medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
IDEAYA Biosciences Investor R&D Day in
Monday, November 16th, 2026, at 5:00 PM GMT
- IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
- The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
- Advance registration is required for both in-person and virtual attendance. To register, please visit https://lifescievents.com/event/izl51pw/
Wells Fargo 21st Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET,
- Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology
Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET,
- Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst
Citi's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET,
- Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
Morgan Stanley 24th Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET,
- Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-london-investor-rd-day-and-participation-in-upcoming-september-2026-investor-conferences-302865528.html
SOURCE IDEAYA Biosciences, Inc.